Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Isofol Medical AB (publ) stock price, quote, forecast and news

ISOFOL.ST
SE0009581051
A2DPV6

Price

2.25 SEK
Today +/-
+0 SEK
Today %
+0 %
P

Isofol Medical AB (publ) Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Isofol Medical AB (publ), a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Isofol Medical AB (publ) from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Isofol Medical AB (publ)’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Isofol Medical AB (publ). Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Isofol Medical AB (publ)’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Isofol Medical AB (publ)’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Isofol Medical AB (publ)’s growth potential.

Isofol Medical AB (publ) Revenue, EBIT and net profit per share

DateIsofol Medical AB (publ) RevenueIsofol Medical AB (publ) EBITIsofol Medical AB (publ) Net Income
2026e3.33 B SEK490.85 M SEK533.25 M SEK
2025e1.33 B SEK352.05 M SEK374.11 M SEK
2024e70.7 M SEK-7.58 M SEK-8.97 M SEK
2023721,000 SEK-41.68 M SEK-37.07 M SEK
202212.8 M SEK-167.54 M SEK-159.79 M SEK
202122.41 M SEK-204.47 M SEK-200.25 M SEK
202037.12 M SEK-186.49 M SEK-188.99 M SEK
20190 SEK-167.8 M SEK-161.58 M SEK
20180 SEK-89.85 M SEK-83.13 M SEK
20170 SEK-72.59 M SEK-72.04 M SEK
20160 SEK-64.95 M SEK-64.95 M SEK
20140 SEK-31.86 M SEK-31.68 M SEK
20130 SEK-35.36 M SEK-33.73 M SEK
20120 SEK-10.53 M SEK-10.6 M SEK

Isofol Medical AB (publ) Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B SEK)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M SEK)EBIT (M SEK)EBIT MARGIN (%)NET INCOME (M SEK)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201220132014201620172018201920202021202220232024e2025e2026e
00000000.040.020.0100.071.333.33
---------40.54-45.45--1,800.00150.00
--------437.84-790.91-1,083.33----
-10-300-58-61-72-137-162-174-130-34000
-10-35-31-64-72-89-167-186-204-167-41-7352490
--------502.70-927.27-1,391.67--10.0026.4714.74
-10-33-31-64-72-83-161-188-200-159-37-8374533
-230.00-6.06106.4512.5015.2893.9816.776.38-20.50-76.73-78.38-4,775.0042.51
16.7816.7816.7826.4748.7856.2956.4477.76125.65161.52161.52000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Isofol Medical AB (publ) Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Isofol Medical AB (publ) is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M SEK)RECEIVABLES (M SEK)OTHER REC. (M SEK)INVENTORIES (M SEK)OTHER CURRENT LIAB. (M SEK)CURRENT ASSETS (M SEK)TANGIBLE ASSETS (M SEK)LONG-T. INVEST. (M SEK)LONG-T. REC. (M SEK)INTANGIBLE ASSETS (M SEK)GOODWILL (M SEK)OTHER NON-CURRENT ASSETS (M SEK)NON-CURRENT ASSETS (M SEK)TOTAL ASSETS (M SEK)LIABILITIESCOMMON STOCK (M SEK)ADDITIONAL PAID-IN CAPITAL (M SEK)RETAINED EARNINGS (M SEK)OTHER EQUITY (M SEK)UNREAL. GAINS/LOSSES (M SEK)EQUITY (M SEK)LIABILITIES (M SEK)PROVISIONS (M SEK)OTHER SHORT-TERM LIAB. (M SEK)SHORT-TERM DEBTS (M SEK)LONG-TERM DEBT PORTION (M SEK)SHORT-TERM REC. (M SEK)LONG-T. LIAB. (M SEK)DEFERRED TAXES (M SEK)OTHER LIAB. (M SEK)LONG-T. LIABILITIES (M SEK)DEBT (M SEK)TOTAL CAPITAL (M SEK)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Isofol Medical AB (publ) provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Isofol Medical AB (publ)'s financial health and stability.

Assets

Isofol Medical AB (publ)'s assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Isofol Medical AB (publ) must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Isofol Medical AB (publ) after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Isofol Medical AB (publ)'s financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M SEK)DEPRECIATION (k SEK)DEFERRED TAXES (M SEK)CHANGES IN WORKING CAPITAL (M SEK)NON-CASH ITEM (M SEK)PAID INTEREST (k SEK)PAID TAXES (M SEK)NET CASH FLOW FROM OPERATING ACTIVITIES (M SEK)CAPITAL EXPENDITURES (M SEK)CASH FLOW FROM INVESTING ACTIVITIES (M SEK)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M SEK)INTEREST INCOME AND EXPENSES (M SEK)NET DEBT CHANGE (M SEK)NET CHANGE IN EQUITY (M SEK)CASH FLOW FROM FINANCING ACTIVITIES (M SEK)CASH FLOW FROM OTHER FINANCING ACTIVITIES (SEK)TOTAL DIVIDENDS PAID (M SEK)NET CHANGE IN CASH FLOW (M SEK)FREE CASH FLOW (M SEK)SHARE-BASED COMPENSATION (M SEK)
201520162017201820192020202120222023
-40-64-72-83-161-188-201-159-37
00001,0001,0001,00000
000000000
31791102414-31-11
010-1022-2-1-4
000001,000000
000000000
-36-46-61-92-147-160-188-192-52
000000000
000000000
000000000
000000000
0000-1-1-1-10
37584005115145200
37584005015045000
---------
000000000
011338-84-145-10263-188-52
-36.9-46.84-62.02-92.46-147.53-160.27-188.43-192.68-52.54
000000000

Isofol Medical AB (publ) stock margins

The Isofol Medical AB (publ) margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Isofol Medical AB (publ). The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Isofol Medical AB (publ).

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Isofol Medical AB (publ)'s sales revenue. A higher gross margin percentage indicates that the Isofol Medical AB (publ) retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Isofol Medical AB (publ)'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Isofol Medical AB (publ)'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the Isofol Medical AB (publ)'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Isofol Medical AB (publ). Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Isofol Medical AB (publ)'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Isofol Medical AB (publ) Margin History

Isofol Medical AB (publ) Gross marginIsofol Medical AB (publ) Profit marginIsofol Medical AB (publ) EBIT marginIsofol Medical AB (publ) Profit margin
2026e-4,773.23 %14.76 %16.04 %
2025e-4,773.23 %26.47 %28.13 %
2024e-4,773.23 %-10.71 %-12.69 %
2023-4,773.23 %-5,781.28 %-5,141.61 %
2022-1,023.02 %-1,309.24 %-1,248.68 %
2021-777.9 %-912.51 %-893.7 %
2020-437.55 %-502.42 %-509.15 %
2019-4,773.23 %0 %0 %
2018-4,773.23 %0 %0 %
2017-4,773.23 %0 %0 %
2016-4,773.23 %0 %0 %
2014-4,773.23 %0 %0 %
2013-4,773.23 %0 %0 %
2012-4,773.23 %0 %0 %

Isofol Medical AB (publ) Stock Sales Revenue, EBIT, Earnings per Share

The Isofol Medical AB (publ) earnings per share therefore indicates how much revenue Isofol Medical AB (publ) has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Isofol Medical AB (publ) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Isofol Medical AB (publ)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Isofol Medical AB (publ)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Isofol Medical AB (publ)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Isofol Medical AB (publ) Revenue, EBIT and net profit per share

DateIsofol Medical AB (publ) Sales per ShareIsofol Medical AB (publ) EBIT per shareIsofol Medical AB (publ) Earnings per Share
2026e20.59 SEK0 SEK3.3 SEK
2025e8.23 SEK0 SEK2.32 SEK
2024e0.44 SEK0 SEK-0.06 SEK
20230 SEK-0.26 SEK-0.23 SEK
20220.08 SEK-1.04 SEK-0.99 SEK
20210.18 SEK-1.63 SEK-1.59 SEK
20200.48 SEK-2.4 SEK-2.43 SEK
20190 SEK-2.97 SEK-2.86 SEK
20180 SEK-1.6 SEK-1.48 SEK
20170 SEK-1.49 SEK-1.48 SEK
20160 SEK-2.45 SEK-2.45 SEK
20140 SEK-1.9 SEK-1.89 SEK
20130 SEK-2.11 SEK-2.01 SEK
20120 SEK-0.63 SEK-0.63 SEK

Isofol Medical AB (publ) business model

Isofol Medical AB (publ) is a Swedish company that was founded in 2006 and is listed on the Nasdaq Stockholm exchange. The company focuses on the development of medical solutions for a wide range of diseases, with a particular emphasis on cancer treatment. Isofol's main product is Modufolin, a proprietary technology that is an advancement of the well-known drug Folic Acid, commonly used in cancer therapy. Modufolin has a longer duration in the body, making it more effective in inhibiting tumor cell growth. Isofol also has a diagnostic division that specializes in developing tests for detecting Vitamin B12 levels in the body, which are crucial for identifying diseases such as dementia and anemia. Isofol Medical AB (publ) is one of the most popular companies on Eulerpool.com.

Isofol Medical AB (publ) SWOT Analysis

Strengths

Isofol Medical AB (publ) has a strong and dedicated research and development team that is focused on developing innovative oncology treatments.

The company has a patented technology, Modufolin®, which has demonstrated positive results in clinical trials and has the potential to improve the outcomes for cancer patients.

Isofol Medical AB (publ) has established collaborations and partnerships with renowned academic institutions and pharmaceutical companies, which provides access to expertise and resources.

Weaknesses

The company is in the early stages of development and does not have any approved products in the market. This poses a risk as the success of the company heavily relies on the outcome of ongoing clinical trials.

Isofol Medical AB (publ) currently has a small market presence and limited financial resources, which may hinder its ability to compete with larger pharmaceutical companies.

The company's success is dependent on obtaining regulatory approvals, which can be a lengthy and challenging process.

Opportunities

The global oncology market is growing rapidly, providing significant opportunities for Isofol Medical AB (publ) to capture market share with its innovative oncology treatments.

There is a need for new and improved cancer treatments, and Isofol Medical AB (publ) has the potential to address this unmet medical need with its unique technology.

Strategic collaborations and partnerships with larger pharmaceutical companies can provide access to additional resources, expertise, and distribution networks.

Threats

Competition in the oncology market is intense, with numerous established companies and new entrants vying for market share. Isofol Medical AB (publ) may face challenges in differentiating its products from competitors.

Changes in regulatory requirements or delays in obtaining approvals can significantly impact the company's timelines and potential market entry.

The company is vulnerable to potential intellectual property disputes and challenges, which could affect its ability to protect its technology and products.

Isofol Medical AB (publ) historical P/E ratio, EBIT, and P/S ratio.

Isofol Medical AB (publ) shares outstanding

The number of shares was Isofol Medical AB (publ) in 2023 — This indicates how many shares 161.515 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Isofol Medical AB (publ) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Isofol Medical AB (publ)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Isofol Medical AB (publ)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Isofol Medical AB (publ)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Isofol Medical AB (publ) dividend history and estimates

In 2023, Isofol Medical AB (publ) paid a dividend amounting to 0.76 SEK. Dividend means that Isofol Medical AB (publ) distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Isofol Medical AB (publ) provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Isofol Medical AB (publ)’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Isofol Medical AB (publ)'s overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Isofol Medical AB (publ) Dividend History

DateIsofol Medical AB (publ) Dividend
20230.76 SEK
Isofol Medical AB (publ) does not pay out any dividends.
Unfortunately, there are currently no price targets and forecasts available for Isofol Medical AB (publ).

Isofol Medical AB (publ) latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2023-0.19 SEK-0.09 SEK (53.1 %)2023 Q1
12/31/2022-0.48 SEK-0.16 SEK (67 %)2022 Q4
9/30/2022-0.32 SEK-0.2 SEK (38.12 %)2022 Q3
6/30/2022-0.32 SEK-0.33 SEK (-2.1 %)2022 Q2
3/31/2022-0.31 SEK-0.3 SEK (4.18 %)2022 Q1
12/31/2021-0.32 SEK-0.38 SEK (-17.57 %)2021 Q4
9/30/2021-0.28 SEK-0.32 SEK (-13.15 %)2021 Q3
6/30/2021-0.26 SEK-0.48 SEK (-82.79 %)2021 Q2
3/31/2021-0.54 SEK-0.4 SEK (25.74 %)2021 Q1
12/31/2020-0.53 SEK-0.52 SEK (0.98 %)2020 Q4
1
2
3

Isofol Medical AB (publ) list of shareholders

%
Name
Stocks
Change
Date
9.86 % Avanza Bank Holding AB15,932,995-303,9543/19/2024
4.73 % Haglund (Christian)7,636,50609/30/2023
3.95 % Swedbank Försäkring AB6,382,690-3,7609/30/2023
3.69 % Franzen (Mats)5,952,39309/30/2023
3.31 % Gustafsson (Goran)5,338,660-299,8489/30/2023
2.82 % Enocson (Hans)4,555,23609/30/2023
2.38 % Ekman (Claes)3,850,00009/30/2023
2.32 % Gustafsson (Bengt)3,749,45909/30/2023
1.89 % Wiklund (Hans)3,044,65909/30/2023
1.84 % Linc AB2,972,4192,972,41912/31/2022
1
2
3

Isofol Medical AB (publ) Executives and Management Board

Mr. Par-Ola Mannefred61
Isofol Medical AB (publ) Independent Chairman of the Board
Compensation 653,000 SEK
Ms. Anna Belfrage61
Isofol Medical AB (publ) Independent Director
Compensation 350,000 SEK
Mr. Robert Marchesani60
Isofol Medical AB (publ) Independent Director
Compensation 288,000 SEK
Mr. Magnus Bjoersne58
Isofol Medical AB (publ) Independent Director
Compensation 263,000 SEK
Ms. Paula Boultbee64
Isofol Medical AB (publ) Independent Director
Compensation 263,000 SEK
1
2
3

Most common questions regarding Isofol Medical AB (publ)

What values and corporate philosophy does Isofol Medical AB (publ) represent?

Isofol Medical AB (publ) represents values of innovation, scientific expertise, and patient-centered care. As a pharmaceutical company, Isofol Medical focuses on developing and commercializing innovative therapies for patients with unmet medical needs in oncology. The company's corporate philosophy revolves around harnessing the potential of its proprietary drug candidate, arfolitixorin, to improve the outcomes and quality of life for cancer patients. Isofol Medical is committed to conducting rigorous scientific research, collaborating with healthcare professionals, and prioritizing patient well-being. Through its dedication to innovation and patient-centric approach, Isofol Medical aims to make a meaningful difference in the field of oncology treatment.

In which countries and regions is Isofol Medical AB (publ) primarily present?

Isofol Medical AB (publ) is primarily present in the countries and regions of Sweden, the United States, and Europe.

What significant milestones has the company Isofol Medical AB (publ) achieved?

Isofol Medical AB (publ) has achieved several significant milestones. The company successfully completed a Phase 2 clinical trial for their lead product candidate, arfolitixorin, in metastatic colorectal cancer patients. They have also received Fast Track designation from the U.S. Food and Drug Administration (FDA) for arfolitixorin, which highlights the potential of their drug to address unmet medical needs. Isofol Medical AB (publ) has secured partnerships with prominent organizations, including Merck KGaA, enabling them to expand their reach and enhance the development of arfolitixorin. These milestones are indicative of the company's commitment to advancing innovative therapies for cancer treatment.

What is the history and background of the company Isofol Medical AB (publ)?

Isofol Medical AB (publ) is a Swedish pharmaceutical company specializing in the development of innovative treatments for patients with advanced colorectal cancer. Established in 2008, Isofol Medical AB has made significant advancements in the field of folate-based therapies. The company's lead product candidate, arfolitixorin, is an investigational drug being evaluated for its potential to enhance the efficacy of standard chemotherapy. Isofol Medical AB has a dedicated team of researchers and professionals working towards improving the outcomes and quality of life for cancer patients. With its commitment to advancing medical science, Isofol Medical AB (publ) aims to become a key player in the oncology pharmaceutical industry.

Who are the main competitors of Isofol Medical AB (publ) in the market?

The main competitors of Isofol Medical AB (publ) in the market include companies such as F. Hoffmann-La Roche Ltd, Novartis AG, Puma Biotechnology Inc., AstraZeneca PLC, and Merck & Co., Inc.

In which industries is Isofol Medical AB (publ) primarily active?

Isofol Medical AB (publ) primarily operates in the pharmaceutical industry.

What is the business model of Isofol Medical AB (publ)?

Isofol Medical AB (publ) operates as a clinical-stage biotech company. The company focuses primarily on developing and commercializing novel therapeutics for the treatment of cancer. Isofol Medical AB (publ)'s business model revolves around the development of its lead compound, arfolitixorin, which is being studied as a potential treatment for colorectal cancer. The company aims to address the unmet medical needs of patients by advancing its innovative drug candidates through various stages of clinical trials. Through strategic partnerships and collaborations, Isofol Medical AB (publ) aims to bring its novel therapies to market and ultimately improve patient outcomes in the field of oncology.

What is the P/E ratio of Isofol Medical AB (publ) 2024?

The Isofol Medical AB (publ) P/E ratio is -40.5.

What is the P/S ratio of Isofol Medical AB (publ) 2024?

The Isofol Medical AB (publ) P/S ratio is 5.14.

What is the AlleAktien quality score of Isofol Medical AB (publ)?

The AlleAktien quality score for Isofol Medical AB (publ) is 4/10.

What is the revenue of Isofol Medical AB (publ) 2024?

The expected Isofol Medical AB (publ) revenue is 70.7 M SEK.

How high is the profit of Isofol Medical AB (publ) 2024?

The expected Isofol Medical AB (publ) profit is -8.97 M SEK.

What is the business model of Isofol Medical AB (publ)

Isofol Medical AB is a biopharmaceutical company specializing in the development of products for cancer treatment. The company is working on the development of innovative therapies for various types of cancer, including those for which there are currently no effective treatments. Its current focus is on the development of a drug called "Modufolin" for the treatment of colorectal cancer, which is expected to be a promising alternative to the current standard therapy. Isofol Medical is also working on the development of another promising cancer drug called Neuostatin-1, which inhibits blood vessel growth and can thus slow down tumor cell growth. The company's business model revolves around collaboration with partners in the industry, science, and research, as well as distribution of its products. It already has distribution partnerships in Europe and the US and aims to expand its product portfolio in other regions of the world. Overall, Isofol Medical aims to develop and bring to market innovative cancer drugs that meet the needs of patients and physicians. It has a strong expertise in biomedical research and collaborates closely with partners in the industry and science to optimize and market its products. Through its focus on innovation and collaboration, Isofol Medical has the potential to become a leading company in cancer research and treatment.

What is the Isofol Medical AB (publ) dividend?

Isofol Medical AB (publ) pays a dividend of 0 SEK distributed over payouts per year.

How often does Isofol Medical AB (publ) pay dividends?

The dividend cannot currently be calculated for Isofol Medical AB (publ) or the company does not pay out a dividend.

What is the Isofol Medical AB (publ) ISIN?

The ISIN of Isofol Medical AB (publ) is SE0009581051.

What is the Isofol Medical AB (publ) WKN?

The WKN of Isofol Medical AB (publ) is A2DPV6.

What is the Isofol Medical AB (publ) ticker?

The ticker of Isofol Medical AB (publ) is ISOFOL.ST.

How much dividend does Isofol Medical AB (publ) pay?

Over the past 12 months, Isofol Medical AB (publ) paid a dividend of 0.76 SEK . This corresponds to a dividend yield of about 33.57 %. For the coming 12 months, Isofol Medical AB (publ) is expected to pay a dividend of 0.76 SEK.

What is the dividend yield of Isofol Medical AB (publ)?

The current dividend yield of Isofol Medical AB (publ) is 33.57 %.

When does Isofol Medical AB (publ) pay dividends?

Isofol Medical AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Isofol Medical AB (publ)?

Isofol Medical AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Isofol Medical AB (publ)?

For the upcoming 12 months, dividends amounting to 0.76 SEK are expected. This corresponds to a dividend yield of 26.5 %.

In which sector is Isofol Medical AB (publ) located?

Isofol Medical AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Isofol Medical AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Isofol Medical AB (publ) from 2/20/2023 amounting to 0.755 SEK, you needed to have the stock in your portfolio before the ex-date on 2/14/2023.

When did Isofol Medical AB (publ) pay the last dividend?

The last dividend was paid out on 2/20/2023.

What was the dividend of Isofol Medical AB (publ) in the year 2023?

In the year 2023, Isofol Medical AB (publ) distributed 0 SEK as dividends.

In which currency does Isofol Medical AB (publ) pay out the dividend?

The dividends of Isofol Medical AB (publ) are distributed in SEK.

All fundamentals about Isofol Medical AB (publ)

Our stock analysis for Isofol Medical AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Isofol Medical AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.